Circulating tumour markers in breast cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue SUPPL. 1, 2004, Pages

  Seregni, Ettore ^a   Coli, Antonio ^b   Mazzucca, Nicola ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Osepdale S Andrea   (Italy)

^c MISERICORDIA HOSPITAL   (Italy)

Author keywords

Breast cancer; CA 15.3; CEA; Cytokeratins; Tumour markers

Indexed keywords

CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; CA 549 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 19 FRAGMENT; MUCIN 1; NEU DIFFERENTIATION FACTOR; ONCOPROTEIN; PROTEIN; TISSUE POLYPEPTIDE ANTIGEN; TISSUE SPECIFIC POLYPEPTIDE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; BODY BURDEN; BONE METABOLISM; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; HUMAN; MOLECULAR BIOLOGY; OUTCOMES RESEARCH; PATIENT MONITORING; PRACTICE GUIDELINE; PROGNOSIS; PROSPECTIVE STUDY; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; VALIDATION PROCESS;

EID: 3042584366     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1523-z     Document Type: Review

References (72)

1. Price MR, Tendler JB. Polymorphic epithelial mucins (PEM): molecular characteristic and association with breast cancer. Breast 1993; 2:3-7.
2. von Mensdorff-Pouilly S, Snijdewint FGM, Verstraeten AA, Verheijen RHM, Kenemans P. Human MUC1 mucin: a multi-faceted glycoprotein. Int J Biol Markers 2000; 15:343-356.
3. Ligtemberg MJL, Buijs F, Vos HL, Hilken J. Suppression of cellular aggregation by high levels of episialin. Cancer Res 1992; 52:2318-2324.
4. Ogata S, Maimonis PJ, Itzkowitz SH. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res 1992; 52:4741-4764.
5. Hudson MJ, Stamp GW, Chaudhary KS, Hewitt R, Stubbs AP, Abel PD, Lalani EN. Human MUC1 mucin: a potent glandular morphogen. J Pathol 2001; 194:373-383.
6. Schreiber J, Stahn R, Schenk JA, Karsten U, Pecher G. Binding of tumor antigen mucin (MUC1) derived peptides to the heat shock protein DnaK. Anticancer Res 2000; 20:3093-3098.
7. Quin RJ, McGuckin MA. Phosphorylation of the cytoplasmic domain of the MUC1 mucin correlates with changes in cell-cell adhesion. Int J Cancer 2000; 87:499-506.
8. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001; 276:13057-13064.
9. Li Y, Kuwahara H, Ren J, Wen G and Kufe D. The c-Src tyrosine kinase regulated signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3β and β-catenin. J Biol Chem 2001; 276:6061-6064.
10. Yin L, Li Y, Ren J, Kuwahara H, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 2003; 278:35458-35464.
11. Kirnarsky L, Prakash O, Vogen SM, Nomoto M, Hollingsworth MA, Sherman S. Structural effects of O-glycosylation on a 15-residue peptide from the mucin (MUC1) core protein. Biochemistry 2000; 39:12076-12082.
12. Norum LF, Sauren AM, Rye PD, Nustad K. New immunoassays for MUC1 breast cancer. Tumor Biol 2001; 22:216-222.
13. Rye PD, McGuckin MA. MUC1: antibodies and immunoassays. Tumor Biol 2001; 22:269-272.
14. Hayes D, Sekine H, Ohao T, Abe M, Keefe K, Kufe DW. Use of murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 1985; 75:1671-1678.
15. Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986; 10:1542-1550.
16. Reddish MA, Helbrecht N, Almeida AF, Madiyalakan R, Suresh MR, Longenecker BM. Epitope mapping of Mab B27.29 within the protein core of the malignant breast carcinoma-associated mucin antigen MUC1. J Tumor Marker Oncol 1992; 7:19-27.
17. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 1965; 121:439-462.
18. Berling B, Kolbinger F, Grunert F, Thompson JA, Brombacher F, Buchegger F, von Kleist S, Zimmermann W. Molecular cloning of a carcinoembryonic antigen (CEA)-gene family-member expressed in leukocytes of chronic myeloid leukemia patients and bone marrow. Cancer Res 1990; 50:6534-6539.
19. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanner C. Carcinoembryonic antigen, a human tumor marker, functions as a intercellular adhesion molecule. Cell 1989; 57:327-334.
20. Steiner PM, Roop DR. Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 1988; 57:593-625.
21. Nagle R. Intermediate filaments: a review of the basic biology. Am J Surg Pathol 1988; 12:4-16.
22. Moll R. Cytokeratins in the histological diagnosis of malignant tumors. Int J Biol Markers 1994; 9:63-69.
23. Bodenmuller H, Donie F, Kaufmann M, Banauch D. The tumor markers TPA, TPS, TPAcyk and CYFRA 21-1 react differently with the keratins 8, 18 and 19. Int J Biol Markers 1994; 9:70-74.
24. Sundrstrom BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. Int J Biol Markers 1994; 9:102-108.
25. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14:2843-2877.
26. American Society of Clinical Oncology. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1998; 16:793-795.
27. Smith TJ, Davisdon NE, Schapira DV, Grunfeld E, Muss HB, Vogel VG III, Somerfield MR for the American Society of Clinical Oncology Breast Cancer Surveillance Expert Panel. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 199; 17:1080-1082.
28. Bast RC, Ravdin P, Hayes DF, et al. for the American Society of Clinical Oncology Tumor Markers Expert Panel. J Clin Oncol 2001; 19:1865-1878.
29. Basuyau JP, Blanc-Vicent MP, Bidart JM, et al. Summary report of the standards, options and recommendations for the use of serum tumour markers on breast cancer: 2000. Br J Cancer 2003; 89:532-534.
30. Molina R, Gion M. Use of blood tumour markers in the detection of recurrent breast cancer. Breast 1998; 7:187-189.
31. Stearns V, Yamauchi H, Hayes DF. Circulating tumor markers in breast cancer: accepted utilities and novel prospects. Breast Cancer Res Treat 1998; 52:239-259.
32. Cheung KL, Graves CRL, Robertson JFR. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000; 26:91-102.
33. Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 2001; 34:347-352.
34. Sturgeon C. Practice guidelines for tumor marker use in the clinic. Clin Chem 2002; 48:1151-1159.
35. Gion M, Mione R, Leon AE, Lüftner D, Molina R, Possinger K, Robertson JF. CA 27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer 2001; 37:355-363.
36. Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. CA 15.3: a prognostic marker in breast cancer. Int J Biol Marker 2000; 15:330-333.
37. Ebeling FG, Stieber P, Untch M, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002; 86:1217-1222.
38. Gion M, Boracchi P, Dittadi R, et al. Prognostic role of serum CA 15.3 in 362 node-negative breast cancers: An old player for a new game. Eur J Cancer 2002; 38:1181-1188.
39. Gaglia P, Caldarola B, Bussone R, et al. Prognostic value of CEA and ferritin assay in breast cancer: a multivariate analysis. Eur J Cancer Clin Oncol 1988; 24:1151-1155.
40. Jong-Bakker MD, Hart AA, Persijn JP, et al. Prognostic significance of CEA in breast cancer: a statistical study. Eur J Cancer Clin Oncol 1981; 17:1307-1313.
41. Cantwell B, Duffy MJ, Fennelly JJ, et al. Carcino-embryonic antigen assay as a guide to tumour bulk, response to therapy and prognosis in human breast cancer. J Med Sci 1980; 149:469-474.
42. Wang DY, Bulbrook RD, Hayward JL, et al. Relationship between plasma carcinoembryonic antigen and prognosis in women with breast cancer. Eur J Cancer 1975; 11:615-618.
43. Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, Hirakawa K. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 2000; 89:1285-1290.
44. Safi F, Kohler I, Rottinger E, et al. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989; 4:207-214.
45. Colomer R, Ruibal A, Genolla J, et al. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989; 13:123-133.
46. Nicolini A, Colombini C, Luciani L, et al. Evaluation of serum CA 15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer 1991; 64:154-158.
47. Repetto L, Onetto M, Gardin G et al. Serum CEA, CA 15-3 and MCA in breast cancer patients: a clinical evaluation. Cancer Detect Prev 1993; 17:411-415.
48. Al-Jarallah MA, Behbeham AE, El-Nass SA, et al. Serum CA 15-3 and CEA patterns in postsurgical follow-up and in monitoring clinical course of metastatic cancer in patients with breast carcinoma. Eur J Surg Oncol 1993; 19:74-79.
49. Soletormos G, Nielsen D, Schioler V, et al. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15-3 compared to CEA and TPA. Ann Oncol 1993; 4:861-869.
50. Markopoulos CJ, Gogas Hj, Alevizou-Terzaki BPH, et al. CA 15-3 in the prediction of recurrence of breast cancer. Breast Dis 1994; 7:1-5.
51. Kokko R, Holli K, Hakama M. CA 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer 2002; 38:1189-1193.
52. Crippa F, Bombardieri E, Seregni E, Castellani MR, Gasparini M, Maffioli L, Pizzichetta M, Buraggi GL. Single determination of CA 15 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer. J Nucl Biol Med 1992; 36:115-116.
53. Bombardieri E, Pizzichetta M, Veronesi P, et al. CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer 1992; 294:144-146.
54. Chan DW, Beveridge RA, Muss H, et al. Use of truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997; 15:2322-2328.
55. Jäger W, Merkle E, Lang N. Increasing serum tumour markers as decision criteria for hormone-therapy of metastatic breast cancer. Tumor Biol 1994; 12:60-66.
56. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by "early" salvage treatment of breast cancer for patients: a retrospective 6-year study. Br J Cancer 1997; 76:1106-1111.
57. Guadagni F, Ferroni P, Carlini S. A re-evaluation of carcino-embryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001; 7:2357-2362.
58. Robertson JFR, Jaeger W, Syzmendera JJ, et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. Eur J Cancer 1999; 35:47-53.
59. Soletormos G, Schioler V, Nielsen D, et al. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 1993; 39:2077-2083.
60. Hayes DF, Kiang DT, Korzun A, Tondini C, Wood W, Kufe D. CA 15.3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clini Oncol 1988; 7:38a.
61. Yasaever V, Camlica H, Karaloglu D, Dalay N. Utility of CA 15.3 in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomenon. Clin Biochem 1997; 30:53-56.
62. Arciero C, Somiari SB, Shriver CD, et al. Functional relationship and gene ontology classification of breast cancer biomarkers. Int J Biol Markers 2003; 18:241-272.
63. Heer K et al. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 2001; 7:3491-3494.
64. Pegram MD, Pauletti G, Slalom DJ. Her-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998; 52:65-77.
65. Mehta RR, McDermott JH, Hieken TJ, Marler KC, Patel MK, Wild LD, Das Gupta TK. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998; 16:2409-2416.
66. Colomer R, Montero S, Lluch A, et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000; 6:2356-2362.
67. Wu JT. c-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta 2002; 322:11-19.
68. Seregni E, Martinetti A, Ferrari L, Bombardieri E. Clinical utility of biochemical marker of bone remodelling in patients with bone metastases of solid tumors. Q J Nucl Med 2001; 45:7-17.
69. Bombardieri E, Martinetti A, Miceli R, Mariani L, Castellani MR, Seregni E. Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer? Eur J Nucl Med 1997; 24:1349-1355.
70. Martinetti A, Bajetta E, Seregni E, et al. Serum markers of bone metastases in post-menopausal breast cancer patients treated with Formestane. Tumor Biol 1997; 18:197-205.
71. Wulfkuhle JD, Liotta LA, Petricoin E. Proteomic application for the early detection of cancer. Nat Rev Cancer 2003; 3:267.
72. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48:1296-1304.